SMARCAL, a chromatin remodeling factor, decreases telomere-replication stress related to carcinogenesis [24, 25], and TLE2 is highly expressed in patients with early stage bladder cancer and correlates with favorable prognosis [26]. Here, SET is linked to urinary bladder cancer.